IMNM Immunome, Inc.
Immunome, Inc. (IMNM) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 94% planned / 6% discretionary
Largest single sale: $8.1M.
Where they traded
Last open-market purchase: June 5, 2026 , by BIENAIME JEAN JACQUES .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Barchas Isaac | Director | Sell 10b5-1 | 11,048 | $27.25 | $301.1K | 92,211 −10.7% of holding | |
| Barchas Isaac | Director | Sell 10b5-1 | 62,291 | $26.23 | $1.6M | None left | |
| Barchas Isaac | Director | Sell 10b5-1 | 10,125 | $26.07 | $264.0K | 62,291 −14% of holding | |
| Barchas Isaac | Director | Sell 10b5-1 | 15,248 | $26.06 | $397.4K | 72,416 −17.4% of holding | |
| Barchas Isaac | Director | Sell 10b5-1 | 20,840 | $26.06 | $543.1K | 87,664 −19.2% of holding | |
| Horn Kinney | CHIEF BUSINESS OFFICER | Sell 10b5-1 | 90,616 | $25.09 | $2.3M | None left | |
| Barchas Isaac | Director | Sell 10b5-1 | 16,906 | $24.20 | $409.1K | 108,504 −13.5% of holding | |
| Horn Kinney | CHIEF BUSINESS OFFICER | Sell 10b5-1 | 1,092 | $25.00 | $27.3K | None left | |
| Barchas Isaac | Director | Sell 10b5-1 | 83,094 | $24.11 | $2.0M | 125,410 −39.9% of holding | |
| Barchas Isaac 2 fills | Director | Sell 10b5-1 | 100,000 | $22.59 | $2.3M | 232,839 −30% of holding | |
| Lechleider Robert 3 fills | Chief Medical Officer | Sell 10b5-1 | 55,000 | $22.62 | $1.2M | 48,091 −53.4% of holding | |
| Barchas Isaac | Director | Sell 10b5-1 | 101,050 | $21.12 | $2.1M | 308,504 −24.7% of holding | |
| Lechleider Robert 2 fills | Chief Medical Officer | Sell 10b5-1 | 55,000 | $19.85 | $1.1M | 30,225 −64.5% of holding | |
| Rosett Max | Chief Financial Officer | Sell 10b5-1 | 60,000 | $18.23 | $1.1M | 54,037 −52.6% of holding | |
| BIENAIME JEAN JACQUES 3 fills | Director | Buy | 10,500 | $19.45 | $204.3K | 43,415 | |
| BIENAIME JEAN JACQUES 2 fills | Director | Sell | 10,500 | $19.41 | $203.8K | 42,915 −19.7% of holding | |
| BIENAIME JEAN JACQUES | Director | Buy | 5,000 | $20.70 | $103.5K | 43,415 | |
| Rosett Max 2 fills | Chief Financial Officer | Sell 10b5-1 | 65,000 | $21.92 | $1.4M | 55,381 −54% of holding | |
| Higgins Jack | Chief Scientific Officer | Sell 10b5-1 | 9,438 | $21.64 | $204.2K | 22,000 −30% of holding | |
| SIEGALL CLAY B | President and CEO | Buy | 25,450 | $19.67 | $500.6K | 690,704 | |
| WAGENHEIM PHILIP | Director | Sell | 28,200 | $20.65 | $582.3K | 341,147 −7.6% of holding | |
| WAGENHEIM PHILIP | Director | Sell | 36,800 | $20.47 | $753.3K | 369,347 −9.1% of holding | |
| BIENAIME JEAN JACQUES | Director | Buy | 1,000 | $21.55 | $21.6K | 38,415 | |
| BIENAIME JEAN JACQUES | Director | Buy | 1,000 | $22.12 | $22.1K | 37,415 | |
| SIEGALL CLAY B | President and CEO | Buy | 4,729 | $21.15 | $100.0K | 665,254 | |
| Barchas Isaac 2 fills | Director | Sell 10b5-1 | 383,200 | $21.74 | $8.3M | 2,042,432 −15.8% of holding | |
| Tsai Philip | Chief Technical Officer | Buy | 10,000 | $20.49 | $204.9K | 43,300 | |
| SIEGALL CLAY B | President and CEO | Buy | 7,278 | $20.48 | $149.1K | 860,525 | |
| SIEGALL CLAY B | President and CEO | Buy | 46,511 | $21.50 | $1000.0K | 853,247 |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.